TY  - JOUR
T1  - Evaluation of functional movement parameters of Parkinson`s patients during ON and OFF states of dopaminergic medication
AU  - Bayram, İsmail
PY  - 2025
DA  - August
Y2  - 2025
DO  - 10.55971/EJLS.1727347
JF  - European Journal of Life Sciences
JO  - Eur J Life Sci
PB  - Anadolu University
WT  - DergiPark
SN  - 2822-5333
SP  - 84
EP  - 93
VL  - 4
IS  - 2
LA  - en
AB  - Parkinson's Disease is a progressive neurodegenerative disease affecting sensory-motor systems and decreasing patients' quality of life. This study aims to find a sophisticated method for detecting characteristics of patients and comparing gait, balance and tremors between the ON and OFF periods. The data provided by the Xsens (Movella) company belongs to 3 anonymous patients, and the content is unique for all 3 patients since they were unable to perform the same movement patterns due to different disease severity. Their descriptive information was not provided due to patient privacy. Tremor, gait and balance assessments were asked to be performed via preferred approaches and methods by using MVN Analyze Software. Kinematic improvements were detected in gait parameters such as cadence (step/min), the number of steps, speed (m/s), total distance (m), stride and length. The provided data shows that patients have some difficulties during turns and initiation of gait (freezing gait). It accompanies a delay in the first step at the beginning of the gait and after turns as well. For the tremor assessment, a heat map was generated based on the magnitude and frequency of the tremors. Both the magnitude and frequency of the tremors were smaller under the dopaminergic medication (ON: amplitude:4.99 cm frequency:4.04 Hz; OFF: amplitude:7.78 cm frequency:5.17 Hz). We were unable to assess the balance due to time limitations. Most of the parameters show an improvement in gait and tremors during the ON period. Results are important in terms of individualization of drug intake time and dosage.
KW  - Drug therapy
KW  - inertial measurement units
KW  - motion analyses
KW  - Parkinson´s disease
CR  - World Health Organization (2022). Parkinson Disease: a Public Health Approach. Technical Brief. Retreived June 9, 2025 from https://www.who.int/publications/i/item/9789240050983
CR  - Silva S, Almeida AJ, Vale N. Importance of nanoparticles for the delivery of antiparkinsonian drugs. Pharmaceutics (2021);13:508. https://doi.org/10.3390/pharmaceutics13040508
CR  - Connolly BS, Lang AE. Pharmacological treatment of Parkinson disease. Jama (2014);311(16):1670-1683. https://doi.org/10.1001/jama.2014.3654
CR  - Malek N, Kanavou S, Lawton M, Pitz V, Grosset KA, Bajaj N, Barker RA, Ben‐Shlomo Y, Burn DJ, Foltynie T, Hardy J, Williams N, Wood N, Morris HR, Grosset DG. L-dopa responsiveness in early Parkinson’s disease is associated with the rate of motor progression. Park Relat Disord. (2019);65:55-61. https://doi.org/10.1016/j.parkreldis.2019.05.022
CR  - Prasad EM, Hung S. Current therapies in clinical trials of Parkinson’s disease: a 2021 update. Pharmaceuticals. (2021);14(8):717. https://doi.org/10.3390/ph14080717
CR  - Chen JJ, Lew M, Siderowf A. Treatment strategies and quality-of-care indicators for patients with Parkinson’s disease. J Manag Care Spec Pharm. (2009);15(3 Supp A):1-22. https://doi.org/10.18553/jmcp.2009.15.s3.1
CR  - Vorovenci RJ, Biundo R, Antonini A. Therapy-resistant symptoms in Parkinson’s disease.  J Neural Transm. (2016);123,19-30. https://doi.org/10.1007/s00702-015-1463-8
CR  - Nonnekes J, Timmer MHM, Vries NM de, Rascol O, Helmich RC, Bloem BR. Unmasking levodopa resistance in Parkinson’s disease. J Mov Disord. (2016);31(11):1602-1609. https://doi.org/10.1002/mds.26712
CR  - Thomas I, Alam M, Bergquist F, Buvarp D, Memedi M, Nyholm D, Westin J. Sensor-based algorithmic dosing suggestions for oral administration of levodopa/carbidopa microtablets for Parkinson’s disease: a first experience. J Neurol. (2019);266(3):651-658. https://doi.org/10.1007/s00415-019-09183-6
CR  - Khanna AJ, Adams J, Antoniades CA, Bloem BR, Carroll C, Cedarbaum JM, Cosman JD, Dexter DT, Dockendorf MF, Edgerton J, Gaetano L, Goikoetxea E, Hill D, Horak FB, Izmailova ES, Kangarloo T, Katabi D, Kopil C, Lindemann M, Mammen JR, Marek K, McFarthing K, Mirelman A, Müller MLTM, Pagano G, Peterschmitt M, Ren J, Rochester L, Sardar S, Siderowf A, Simuni T, Stephenson D, Swanson‐Fischer C, Wagner JA, Jones GB. Accelerating Parkinson’s disease drug development with federated learning approaches. npj Parkinsons Dis Nature Portfolio. (2024);10(1):225. https://doi.org/10.1038/s41531-024-00837-5
CR  - Jankovic J. Parkinson’s disease: clinical features and diagnosis. J Neurol Neurosurg Psychiatry. (2008);79(4):368-376. https://doi.org/10.1136/jnnp.2007.131045
CR  - Ertan H, Bayram İ. Fundamentals of human movement, its control and energetics. In Comparative Kinesiology of the Human Body. London: Elsevier; (2020). p. 29-45. ISBN: 978-0-12-812162-7
CR  - Altan E, Seide SE, Bayram İ, Gizzi L, Ertan H, Röhrle O. A systematic review and meta-analysis on the longitudinal effects of unilateral knee extension exercise on muscle strength. Front Sports Act Living. (2020);2:518148.  https://doi.org/10.3389/fspor.2020.518148
CR  - Stephenson D, Alexander R, Aggarwal V, Badawy R, Bain LJ, Bhatnagar R, Bloem BR, Boroojerdi B, Burton J, Cedarbaum JM, Cosman JD, Dexter DT, Dockendorf MF, Dorsey ER, Dowling AV, Evers LJW, Fisher K, Frasier M, Garcia‐Gancedo L, Goldsack JC, Hill D, Hitchcock JM, Shulman J, Lawton MP, Lee SH, Lindemann M, Marek K, Mehrotra N, Meinders MJ, Minchik M, Oliva L, Romero K, Roussos G, Rubens R, Sadar S, Scheeren J, Sengoku E, Simuni T, Stebbins GT, Taylor KI, Yang B, Zach N. Precompetitive consensus building to facilitate the use of digital health technologies to support parkinson disease drug development through regulatory science. Digit Biomark. (2020);4(Suppl. 1):28–49. https://doi.org/10.1159/000512500
CR  - Titova N, Levin О, Кatunina Е, Chaudhuri КR. ‘Levodopa Phobia’: a review of a not uncommon and consequential phenomenon. npj Parkinsons Dis Nature Portfolio. (2018);4:31. https://doi.org/10.1038/s41531-018-0067-z
CR  - Rhyu HS, Rhi SY. The effects of training on different surfaces, on balance and gait performance in stroke hemiplegia. Rev Bras Med Esporte. (2021);27:592-596. https://doi.org/10.1590/1517-8692202127062020_0089
CR  - Fine AS, Kaufman ML, Goodman J, Turk BR, Bastian AJ, Lin D, Fatemi A, Keller J. Wearable sensors detect impaired gait and coordination in LBSL during remote assessments. Ann Clin Transl Neurol. (2022);9(4):468. https://doi.org/10.1002/acn3.51509
CR  - Pandis MFD, Tomino C, Proietti S, Rotondo R, Gaglione M, Casali M, Corbo M, Biase L di, Galli M, Goffredo M, Stocchi F. Mechanical peripheral stimulation for the treatment of gait disorders in patients with Parkinson’s disease: a multi-centre, double-blind, crossover randomized controlled trial. J NeuroEng Rehabil. (2025);22:77. https://doi.org/10.1186/s12984-025-01574-3
CR  - Slevin JT, Gerhardt GA, Smith CD, Gash DM, Kryscio RJ, Young B. Improvement of bilateral motor functions in patients with Parkinson disease through the unilateral intraputaminal infusion of glial cell line—derived neurotrophic factor. J Neurosurg. (2005);102(2):216-222. https://doi.org/10.3171/jns.2005.102.2.0216
CR  - Mancini M, Afshari M, Almeida QJ, Huffmaster SLA, Balfany K, Camicioli R, Christiansen CL, Dale ML, Dibble LE, Earhart GM, Ellis TD, Griffith G, Hackney ME, Hopkins JO, Horak FB, Jones KE, Li L, O’Keefe JA, Kwei K, Olivier GN, Rao AK, Sivaramakrishnan A, Corcos DM. Digital gait biomarkers in Parkinson’s disease: susceptibility/risk, progression, response to exercise, and prognosis. npj Parkinsons Dis Nature Portfolio. (2025);11:51. https://doi.org/10.1038/s41531-025-00897-1
CR  - Muñoz B, Valderrama J, Paredes JDA, Pino YJC, Navarro A, Orozco JL. Objective arm swing analysis in early-stage parkinson’s disease using an rgb-d camera (Kinect®)1. J Parkinsons Dis. (2018);8(4):563-570. https://doi.org/10.3233/jpd-181401
CR  - Pieterman M, Adams S, Jog M. Method of levodopa response calculation determines strength of association with clinical factors in Parkinson disease. Front Neurol. (2018);9:260. https://doi.org/10.3389/fneur.2018.00260
CR  - Radder DLM, Lima ALS de, Domingos J, Keus SHJ, Nimwegen M van, Bloem BR, Vries NM de. Physiotherapy in Parkinson’s disease: a meta-analysis of present treatment modalities. Neurorehabil Neural Repair. (2020);34(10):871-880. https://doi.org/10.1177/1545968320952799
CR  - Helmich RC, Bloem BR, Toni I. Motor imagery evokes increased somatosensory activity in parkinson’s disease patients with tremor. Hum Brain Mapp. (2012);33:1763-1779. https://doi.org/10.1002/hbm.21318
CR  - Palermo G, Giannoni S, Bellini G, Siciliano G, Ceravolo R. Dopamine transporter imaging, current status of a potential biomarker: A comprehensive review. Int J Mol Sci. (2021);22(20):11234. https://doi.org/10.3390/ijms222011234
CR  - Islam MdS, Rahman W, Abdelkader A, Lee S, Yang PT, Purks JL, Adams J, Schneider RB, Dorsey ER, Hoque E. Using AI to measure Parkinson’s disease severity at home. npj Digit Med. (2023);6:156. https://doi.org/10.1038/s41746-023-00905-9
CR  - Padilla-Godínez FJ, Ruiz-Ortega LI, Guerra‐Crespo M. Nanomedicine in the face of Parkinson’s disease: from drug delivery systems to nanozymes. Cells. (2022);11(21): 3445. https://doi.org/10.3390/cells11213445
CR  - Lawton M, Ben‐Shlomo Y, May M, Baig F, Barber TR, Klein J, Swallow DMA, Malek N, Grosset KA, Bajaj N, Barker RA, Williams N, Burn DJ, Foltynie T, Morris HR, Wood N, Grosset DG, Shulman J. Developing and validating Parkinson’s disease subtypes and their motor and cognitive progression. J Neurol Neurosurg Psychiatry. (2018);89:1279-1287. https://doi.org/10.1136/jnnp-2018-318337
CR  - Monge‐Fuentes V, Mayer AB, Lima MR, Geraldes LR, Zanotto LN, Moreira KG, Martins OP, Piva HL, Felipe MSS, Amaral AC, Bocca AL, Tedesco AC, Mortari MR. Dopamine-loaded nanoparticle systems circumvent the blood–brain barrier restoring motor function in mouse model for Parkinson’s Disease. Sci Rep. (2021);11:15185. https://doi.org/10.1038/s41598-021-94175-8
CR  - Grétarsdóttir HM, Widman E, Johansson A, Nyholm D. Personalized medicine approach in treating parkinson’s disease, using oral administration of levodopa/carbidopa microtablets in clinical practice. J Pers Med. (2021);11(8):720. https://doi.org/10.3390/jpm11080720
CR  - He X, Mo C, Zhang Y, Cai Y, Yang X, Qian Y, Xiao Q. Effect of acute levodopa up-titration on blood pressure in patients with early stage Parkinson’s disease: results of a levodopa challenge test. Front Aging Neurosci. (2022);13:778856. https://doi.org/10.3389/fnagi.2021.778856
CR  - Catalán MJ, Antonini A, Calopa M, Băjenaru O, Fábregues O de, Mínguez‐Castellanos A, Odin P, García-Moreno JM, Pedersen SW, Pirtošek Z, Kulisevsky J. Can suitable candidates for levodopa/carbidopa intestinal gel therapy be identified using current evidence? eNeurologicalSci. (2017);8:44-53. https://doi.org/10.1016/j.ensci.2017.06.004
CR  - Laar T van, Chaudhuri КR, Antonini A, Henriksen T, Trošt M. Infusion therapies in the treatment of Parkinson’s disease. J Parkinsons Dis. (2023);13(5):641-657. https://doi.org/10.3233/jpd-225112
CR  - Kalia LV, Lang AE. Parkinson’s disease. The Lancet. (2015);386(9996):896-912. https://doi.org/10.1016/s0140-6736(14)61393-3
CR  - Georgy EE, Barsnley S, Chellappa R. Effect of physical exercise-movement strategies programme on mobility, falls, and quality of life in Parkinson’s disease. Int J Ther Rehabil. (2012);19(2):88-96. https://doi.org/10.12968/ijtr.2012.19.2.88
UR  - https://doi.org/10.55971/EJLS.1727347
L1  - https://dergipark.org.tr/en/download/article-file/4991277
ER  -